Department of Radiology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Department of Nuclear Medicine, Netherlands Cancer Institute, Amsterdam, The Netherlands.
Crit Rev Oncol Hematol. 2022 Jul;175:103713. doi: 10.1016/j.critrevonc.2022.103713. Epub 2022 May 20.
A range of CT characteristics with potential prognostic value have previously been identified for gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs). Still, there is no widely accepted consensus on which characteristics should be reported as prognostic factors. This systematic review therefore aims to provide an overview of the available literature regarding CT characteristics and their prognostic significance for GEP-NET patients.
PubMed, Embase, and Scopus/Cochrane Library databases were searched and a forward and backward reference check of the identified studies was executed. Eligible studies were conducted in patients with GEP-NET, and reported on the prognostic significance (in terms of tumor grade, spread of disease, and survival) of CT-based biomarkers. Study selection, quality assessment and data extraction were performed by two reviewers independently, resolving disagreement by consensus.
In total, 5074 unique studies were identified, of which 37 were included. Given the paucity of data on GEP-NETs other than PNET, data extraction and analyses was restricted to PNETs. Fourteen CT characteristics were correlated to prognostic outcomes. Larger tumor size, hypo-enhancement, irregular shape and ill-defined margins, presence of locally invasive growth, lymphadenopathy and metastases were predictors of poorer prognosis according to 65-89% of the available studies. Most studies were regarded as having a low (65%) or moderate (24%) risk of bias.
Evidence regarding prognostic value of CT-based biomarkers for PNETs is limited to heterogeneous, retrospective studies. Nonetheless, heterogeneity in data is more likely to obscure than to overestimate any correlation. Therefore, we feel that the before-mentioned characteristics should be regarded and reported as clinically relevant predictors of poorer prognosis.
先前已经确定了一系列具有潜在预后价值的 CT 特征,可用于胃-肠-胰腺神经内分泌肿瘤(GEP-NET)。然而,对于哪些特征应该被报告为预后因素,尚无广泛接受的共识。因此,本系统综述旨在提供有关 GEP-NET 患者 CT 特征及其预后意义的可用文献综述。
在 PubMed、Embase 和 Scopus/Cochrane 图书馆数据库中进行了搜索,并对确定的研究进行了向前和向后的参考文献检查。合格的研究是在 GEP-NET 患者中进行的,并报告了基于 CT 的生物标志物的预后意义(肿瘤分级、疾病扩散和生存)。由两名审查员独立进行研究选择、质量评估和数据提取,并通过共识解决分歧。
总共确定了 5074 个独特的研究,其中 37 个被纳入。鉴于除 PNET 以外的 GEP-NET 数据稀缺,数据提取和分析仅限于 PNET。14 个 CT 特征与预后结果相关。根据 65%-89%的可用研究,较大的肿瘤大小、低增强、不规则形状和不清晰的边界、局部侵袭性生长、淋巴结病和转移是预后较差的预测因素。大多数研究被认为具有低(65%)或中等(24%)偏倚风险。
关于 PNET 基于 CT 的生物标志物预后价值的证据仅限于异质的回顾性研究。尽管如此,数据的异质性更有可能掩盖而不是高估任何相关性。因此,我们认为上述特征应被视为并报告为预后较差的临床相关预测因素。